Neoadjuvant Breast Cancer Trials: Translational Research in Drug Development

Julia A. Beaver, Laleh Amiri-Kordestani, Reena Philip, Patricia Cortazar

Research output: Contribution to journalReview articlepeer-review


In addition to reducing the size and extent of locally advanced breast cancer tumors, neoadjuvant trials allow for rapid assessment of drug efficacy and could expedite development and approval of treatments for early breast cancer. For these reasons, clinical trials in the neoadjuvant setting are prime opportunities to study translational science, pathologic response, genetic biomarkers, and imaging biomarkers. In this review, we provide a summary of the efforts to identify biomarkers aimed to understand tumor biology and to prognosticate and predict response to neoadjuvant therapy for early breast cancer. We also provide a perspective on how neoadjuvant trials can be used to pursue translational research and drug development.

Original languageEnglish (US)
Pages (from-to)151-160
Number of pages10
JournalCurrent Breast Cancer Reports
Issue number3
StatePublished - Sep 24 2015
Externally publishedYes


  • Assessment
  • Biomarkers
  • Clinical trials
  • Drug development
  • Drug efficacy
  • Neoadjuvant trials

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Neoadjuvant Breast Cancer Trials: Translational Research in Drug Development'. Together they form a unique fingerprint.

Cite this